CD57 is recognized as a marker of terminal differentiation with CD57+ NK cells exhibiting reduced proliferation yet heightened cytotoxicity against tumor cells compared to CD57− NK cells [29]. This evidence concerns the gene B3GAT1 and neoplasm.